Verrica Pharmaceuticals Inc.
VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating commoā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$3.46
Price-3.35%
-$0.12
1Y
Price
Market Cap
$32.682m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years+20.0%
EBITDA Margin+1.6%
Net Profit Margin-79.1%
Free Cash Flow MarginRevenue
$14.704m
+94.3%
1y CAGR+32.9%
3y CAGR+18.5%
5y CAGREarnings
-$48.600m
+36.5%
1y CAGR-50.4%
3y CAGR-30.3%
5y CAGREPS
-$8.30
+43.8%
1y CAGR-20.8%
3y CAGR-4.4%
5y CAGRBook Value
-$17.484m
$39.107m
Assets$56.591m
Liabilities$38.892m
DebtDebt to Assets
99.5%
-1x
Debt to EBITDAFree Cash Flow
-$47.359m
+22.3%
1y CAGR-46.6%
3y CAGR-26.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company